Zydus Cadila gets final USFDA nod for Betamethasone Dipropionate Ointment
Betamethasone Dipropionate Ointment is used to treat a variety of skin conditions
Ahmedabad: Zydus Cadila has received final approval from the USFDA to market Betamethasone Dipropionate Ointment USP, 0.05% (US RLD: Betamethasone Dipropionate Ointment).
Betamethasone Dipropionate Ointment is used to treat a variety of skin conditions (e.g., eczema, dermatitis, allergies, rash). The ointment will be manufactured at the group's Topical manufacturing facility at Ahmedabad.
The group now has 293 approvals and has so far filed over 390 ANDAs since the commencement of the filing process in FY 2003-04.
Read also: COVID-19 Drug: Zydus Cadila gets Mexican nod to test Desidustat
Zydus Cadila is a global pharmaceutical company headquartered in Ahmedabad, India. The company discovers, develops, manufactures, and markets a broad range of healthcare therapies.
The group has manufacturing sites and research facilities spread across five states of Gujarat, Maharashtra, Goa, Himachal Pradesh and Sikkim in India and in the US and Brazil.
Read also: Zydus Cadila starts human trails of COVID-19 vaccine ZyCoV-D
